NASDAQ · Biotechnology · USD
Radiopharm Theranostics Limited (RADX) Stock Analysis
Radiopharm Theranostics Limited (RADX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
RADX Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.96
- Previous Close
- $0.99
- Day's Range
- 0.90–1.00
- 52-Week Range
- 0.90–16.25
- Volume
- 14.36K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.86
Valuation
- Market Cap
- $14.28M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 1.11
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −3.64
Financials (FY)
- Revenue (FY)
- $3.63M+1,114.27%
- Net Income (FY)
- −$38.34M
- Shares Outstanding
- 14.59M
- 1-Year Return
- −83.85%
Dividend and dates
- Avg Volume
- 88.82K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, RADX closed at $0.98, −83.85% over 1 year.
Radiopharm Theranostics Limited (RADX) has a market capitalization of $14.28M.
In fiscal 2025, RADX reported revenue of $3.63M.
RADX Stock Return by Calendar Year
Radiopharm Theranostics Limited (RADX) return since Dec 2024: what $10,000 became
- 1 year
- $10,000 $1,615
- −83.85%
- Since Dec 2024
- $10,000 $554
- −94.46%
If you had invested $10,000 in Radiopharm Theranostics Limited (RADX) at the close on December 5, 2024, the earliest close on record here, it would have been worth $554 at the close on October 21, 2026: −94.46% in total, −78.62% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −81.25% |
| 2025 | +16.26% |
| 2024 (partial year) | −74.59% |
As of October 21, 2026.
RADX Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $3.63M | −$38.34M | −1,055.3% |
| 2024 | $299.23K | −$47.95M | −16,024.3% |
| 2023 | $292.36K | −$34.61M | −11,838.6% |
| 2022 | $8.83K | −$30.34M | −343,550.9% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $3.63M | $39.28K | −$34.64M | −$38.34M | −1,055.3% |
| 2024 | $299.23K | $299.23K | −$37.17M | −$47.95M | −16,024.3% |
| 2023 | $292.36K | $292.36K | −$31.69M | −$34.61M | −11,838.6% |
| 2022 | $8.83K | $8.83K | −$19.92M | −$30.34M | −343,550.9% |
Annual figures as reported, in the company's reporting currency. As of June 30, 2025.
RADX Valuation vs Biotechnology Median
Median of 608 stocks| Metric | RADX | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 1.11 | 13.30 | 0.1x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
YahooRadiopharm Theranostics Announces Completion Of EOP2 Meeting With FDA Regarding RAD101, Investigational Radiopharmaceutical Imaging Agent For Detection Of Brain Metastases
BenzingaRadiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting
YahooRadiopharm Says Data From Interim Analysis Of Phase 2b Imaging Clinical Trial Of 18F-RAD101 In Participants With Suspected Recurrent Brain Metastases From Solid Tumors Selected For Presentation At SNO26 Annual Meeting
BenzingaRadiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma
YahooRadiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma
Benzinga
All 9 articles ↓Show fewer ↑
Radiopharm Doses First Patient In Second Cohort Of Its First-In-Human Phase 1/2a Clinical Trial Of RV-01 In Patients With B7-H3 Expressing Tumors
BenzingaRadiopharm Theranostics Schedules An FDA End-Of-Phase 2 For October 1, 2026, To Align On The Design Of A Pivotal Phase 3 Trial To Evaluate RAD101 In Patients With Suspected Recurrence Of Brain Metastases Following Radiotherapy
BenzingaRADX: RAD101 Topline & FY:26 Cash Flows
Yahoo
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B